Pfizer Reaches Patent Settlements with Generic Drugmakers, Extending Vyndamax Protection
Pfizer has settled with Hikma, Cipla, and Dexcel to extend patent protection for its drug Vyndamax until 2031. This settlement delays generic competition that was expected in 2029, providing stability as the drug contributed $6.3 billion in revenue in 2025.
Topics: drug revenue patents pharmaceuticals settlement stock outlook